Private EquityScreenerRefer

MARKET INSIGHTS

  • EventsNEWPrivate market milestones
  • NewsPrecize daily pulse
  • BlogsIn-depth articles and opinions

GUIDES

Explore Now
  • Unlisted SharesStep-by-step · KYC
  • BuyingStep-by-step · KYC
  • SellingExit in 24 - 48 hours
  • Pre-IPOReturns · risks · case studies
  • Tax GuideBudget 2026 changes
  1. Home
  2. Shares
  3. Anglo French Drugs and Industries

Anglo French Drugs and Industries Unlisted Share Price Today

ISIN INE570E01016.

Anglo-French Drugs & Industries is an Indian pharmaceutical manufacturing company engaged in the production and marketing of pharmaceutical formulations and healthcare products. The company primarily focuses on branded generic medicines across therapeutic segments such as antibiotics, vitamins, gastrointestinal treatments, and other prescription drugs. Founded in 1923, the company has over a century of operating history in the Indian pharmaceutical sector and operates its manufacturing facili…

Anglo French Drugs and Industries

Login for availability
Anglo French Drugs and Industries

Anglo French Drugs and Industries Unlisted Share Price Today

Current Price
Login for availability
Loading chart data...
SectorHealthcare & Pharmaceuticals
ISININE570E01016
Depository
Market Cap₹255.61 Cr
P/E Ratio11.2
ROE (%)16.78
Revenue₹90.32 Cr
Book Value1305.22
Debt to Equity0.16
Face Value10
52W High₹2666
52W Low₹2261
Market Cap₹255.61 Cr
P/E Ratio11.2
ROE (%)16.78
Revenue₹90.32 Cr
Book Value1305.22
Debt to Equity0.16
52W High/Low₹2666 / ₹2261
Face Value10
As of FY26

About the company & Industry

Anglo-French Drugs & Industries is an Indian pharmaceutical manufacturing company engaged in the production and marketing of pharmaceutical formulations and healthcare products. The company primarily focuses on branded generic medicines across therapeutic segments such as antibiotics, vitamins, gastrointestinal treatments, and other prescription drugs.

Founded in 1923, the company has over a century of operating history in the Indian pharmaceutical sector and operates its manufacturing facility in Bengaluru, Karnataka. Anglo-French Drugs distributes its products mainly in the domestic market through pharmaceutical distributors and healthcare professionals.

The company operates in the formulations segment, generating revenue primarily from the sale of finished dosage pharmaceutical products. While smaller in scale compared to large pharmaceutical companies, it maintains a diversified product portfolio and continues to operate in India’s highly competitive generic drug market.

Anglo-French Drugs & Industries is an Indian pharmaceutical manufacturing company engaged in the production and marketing of pharmaceutical formulations and healthcare products. The company primarily focuses on branded generic medicines across therapeutic segments such as antibiotics, vitamins, gastrointestinal treatments, and other prescription drugs.

Founded in 1923, the company has over a century of operating history in the Indian pharmaceutical sector and operates its manufacturing facility in Bengaluru, Karnataka. Anglo-French Drugs distributes its products mainly in the domestic market through pharmaceutical distributors and healthcare professionals.

The company operates in the formulations segment, generating revenue primarily from the sale of finished dosage pharmaceutical products. While smaller in scale compared to large pharmaceutical companies, it maintains a diversified product portfolio and continues to operate in India’s highly competitive generic drug market.

Financials

Core Revenue Declined Over the Period

Revenue from operations fell from ₹154 Cr in FY21 to ₹90 Cr in FY26, reflecting a shrinking core business base.

Highly Volatile Earnings Profile

The company reported extreme swings in profitability, with exceptionally high margins in FY23 followed by losses in FY24, indicating possible one-off or non-operating income impact.

Strong Recovery in FY26

FY26 saw a sharp rebound with EBITDA rising to ₹28 Cr and PAT to ₹23 Cr, while EPS jumped 226% YoY, indicating improving profitability momentum.

Income Statement

Revenue(Figures in Cr.)

Core Revenue Declined Over the Period

Revenue from operations fell from ₹154 Cr in FY21 to ₹90 Cr in FY26, reflecting a shrinking core business base.

Highly Volatile Earnings Profile

The company reported extreme swings in profitability, with exceptionally high margins in FY23 followed by losses in FY24, indicating possible one-off or non-operating income impact.

Strong Recovery in FY26

FY26 saw a sharp rebound with EBITDA rising to ₹28 Cr and PAT to ₹23 Cr, while EPS jumped 226% YoY, indicating improving profitability momentum.

Income Statement

Revenue(Figures in Cr.)

Competitive Position

Market Share

P/E Ratio

Financial Ratio Comparison (FY26)

Particulars
Anglo French Drugs and Industries
Indoco Remedies
Albert David
Revenue (₹ Cr)90.321792.94333.60
Revenue Growth (%)2.889.24-2.81
EBITDA Margin (%)31.117.933.87
Net Profit Margin (%)25.30-5.50-0.45
ROE (%)16.78-10.12-0.38
Debt to Equity0.161.110.07
Asset Turnover Ratio (x)0.450.710.65
ROCE (%)15.95--
Interest Coverage Ratio (x)12.290.131.20
ROA (%)11.48--
Working Capital Intensity (x)1.420.080.78

Market Share

P/E Ratio

Financial Ratio Comparison (FY26)

Particulars
Anglo French Drugs and Industries
Indoco Remedies
Albert David
Revenue (₹ Cr)90.321792.94333.60
Revenue Growth (%)2.889.24-2.81
EBITDA Margin (%)31.117.933.87
Net Profit Margin (%)25.30-5.50-0.45
ROE (%)16.78-10.12-0.38
Debt to Equity0.161.110.07
Asset Turnover Ratio (x)0.450.710.65
ROCE (%)15.95--
Interest Coverage Ratio (x)12.290.131.20
ROA (%)11.48--
Working Capital Intensity (x)1.420.080.78

Management

Shareholding PatternAs of FY26
Promoters
64.84%
Life Insurance Corporation of India (LIC)
7.04%
Others
28.12%

Key Managerial Personnel

As of FY26
NameDesignation and Experience
Mr. Abhay Kanoria
Chairman & Managing Director
Mr. Nirbhay Abhay Kanoria
Chief Financial Officer

Shareholding PatternAs of FY26
Promoters
64.84%
Life Insurance Corporation of India (LIC)
7.04%
Others
28.12%

Key Managerial Personnel

As of FY26
NameDesignation and Experience
Mr. Abhay Kanoria
Chairman & Managing Director
Mr. Nirbhay Abhay Kanoria
Chief Financial Officer
Coming Soon

Register to view prices and access exclusive investments.

Minimum ticket ₹10,000 - Start small. No large capital lock-in.
Reserve Access
or
Continue with Google
Reserve Access

FAQs on Anglo French Drugs and Industries Unlisted Shares

What is the unlisted share price today?

unlisted share price is updated regularly on Precize. Visit Precize to check price movements and market trends.

How do I buy unlisted shares?

Register on Precize.in, complete KYC, select , enter quantity, and pay via UPI or NEFT. Shares are transferred within 24 hours.

What is 's revenue and profitability?

Please read these important legal notices and disclosures

None of the information displayed on or downloadable from https://www.precize.in represents an offer to buy or sell or a solicitation of an offer to buy or sell any security, nor does it constitute an offer to provide investment advice or service. Registered representatives of precize do not (1) Advise any member on the merits or advisability of a particular investment or transaction, or (2) Assist in the determination of fair value of any security or investment, or (3) Provide legal, tax, or transactional advisory services.

Read more

© 2026 Precize All Rights Reserved.

DECLARATION OF RISKTERMS OF USEPRIVACY POLICY
reported revenue of ₹90.32 Cr in FYFY26. PAT was ₹22.85 Cr. See full financials on this page.

What is the minimum investment for unlisted shares?

Minimum investment for unlisted shares starts from ₹10000. Please log in to view the latest pricing and availability